<DOC>
	<DOCNO>NCT00280748</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Pemetrexed may stop growth tumor cell block enzymes need cell growth . Giving radiation therapy together pemetrexed may kill tumor cell . PURPOSE : This phase II trial study well give whole-brain radiation therapy together pemetrexed work treat patient brain metastases non-small cell lung cancer .</brief_summary>
	<brief_title>Whole-Brain Radiation Therapy Pemetrexed Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate response patient intracranial brain metastasis non-small cell lung cancer treat whole-brain radiotherapy pemetrexed disodium . Secondary - Determine toxicity regimen patient . - Estimate overall survival patient treat regimen . - Evaluate functional status patient treat regimen . - Assess neurological function progression patient treat regimen . - Determine response patient extracranial disease treat pemetrexed disodium . OUTLINE : Patients undergo whole-brain radiotherapy 5 day week 3 week begin day 1 . Patients also receive pemetrexed disodium IV day 1 , 2 , 3 day 28 course 1 , day 1 subsequent course . Treatment pemetrexed disodium repeat every 21 day total 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 2 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Must evidence brain metastasis MRI CT scan No single brain metastasis oligometastatic disease amenable surgical resection radiosurgery Relapsed NSCLC brain metastasis allow Not candidate doubleagent platinumbased chemotherapy No leptomeningeal metastases No clinically relevant ( defined physical exam ) pleural effusion ascites control drainage procedure PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % OR ≥ 70 year age Life expectancy &gt; 3 month ANC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin ≥ 8 g/dL AST ALT &lt; 3 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Creatinine clearance ≥ 45 mL/min No contraindication intolerance corticosteroid therapy No malignancy within past 5 year diseasefree OR prognosis best define NSCLC opinion attend physician Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity No severe hypersensitivity pemetrexed disodium Able discontinue NSAIDs ≥ 5 day No history underlie dementia , Parkinson 's disease , Alzheimer 's disease Able take vitamin , folic acid , corticosteroid PRIOR CONCURRENT THERAPY : Recovered prior oncologic major surgery Prior resection brain metastasis site brain metastasis allow provide radiologically evaluable intracranial metastases No prior cranial irradiation , include stereotactic radiosurgery More 30 day since prior nonapproved investigational drug No concurrent chemotherapy , immunotherapy , hormonal therapy , radiotherapy , surgery , experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>